preclinical white papers and articles

  1. Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us 9/22/2026

    Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.

  2. 5 Questions That Reveal Whether A Drug Programme Is Built To Succeed 9/22/2026

    Explore how Question-Based Drug Development helps teams build knowledge, reduce avoidable surprises and make stronger scientific and investment decisions.

  3. Déjà vu? A Decade At AAIC, And The Endpoints Haven't Moved 9/16/2026

    Cognitive endpoints in Alzheimer's trials haven't kept pace with the shift to earlier-stage treatment. Modern trials need tools built to catch subtle change.

  4. Your 6-Step Path To AI-Ready Data 8/27/2026

    Struggling with siloed or inconsistent trial data? This guide outlines a clear path to cleaner, governed, AI-ready datasets.

  5. Receptor Occupancy In The Era Of Multispecific Therapeutics 8/21/2026

    Receptor occupancy studies face new challenges as multispecific therapeutics introduce complex target engagement, receptor trafficking, cellular interactions, and assay interpretation considerations.

  6.  Life Sciences Meetings Need More Than Logistics 8/6/2026

    Life sciences meetings often extend beyond investigators’ meetings. Strong planning helps teams support clinical, commercial, governance, and internal programs without adding pressure to the host team.

  7. The Expanding Role Of GLP-1 Receptor Agonists In CNS Clinical Research 7/31/2026

    Metabolic drugs show promise for brain disorders. Emerging evidence suggests they reduce addictive behaviors and may help treat neurodegenerative diseases, opening new pathways for addiction and neurological care.

  8. 2026 Trends Shaping CNS Clinical Research 7/30/2026

    Central nervous system (CNS) trials are rapidly evolving. Learn how fit-for-purpose protocol design, centralized eligibility review, and novel modalities elevate clinical success.

  9. Rapid Expansion Of Peptide And Nanobody Drug Conjugates 7/21/2026

    Peptide and nanobody drug conjugates are gaining momentum, with 106 active programs identified globally. Learn more about the fast-evolving space for targeted drug delivery and competitive opportunities.

  10. The Psychedelic Setback: What MDMA Rejection Taught Drug Developers 6/25/2026

    Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.